Safety and immunogenicity of a split-virion AS03 A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults

Journal of the Formosan Medical Association

Volumn 111, Issue 6, 2012, Pages 333-339

  Yang, Pan Chyr ^a   Yu, Chong Jen ^a   Chang, Shan Chwen ^a   Hsieh, Szu Min ^a   Drame, Mamadou ^b   Walravens, Karl ^c   Roman, François ^c   Gillard, Paul ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; H5N1; Influenza; Prepandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE; THIOMERSAL;

ADULT; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHIVERING; SIDE EFFECT; SINGLE BLIND PROCEDURE; SORE THROAT; SWEATING; TAIWAN; VACCINATION;

ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; PRESERVATIVES, PHARMACEUTICAL; TAIWAN; THIMEROSAL; YOUNG ADULT;

EID: 84862853292     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2011.02.006     Document Type: Article

References (19)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 18 October 2010. Global alert and response (GAR) [Internet]. Available from: [accessed 9.11.10]. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_10_18/en/index.html.
2. Melidou A., Gioula G., Exindari M., Chatzidimitriou D., Diza-Mataftsi E. Influenza A (H5N1): an overview of the current situation. Eurosurveillance 2009, 14:1-4.
3. Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. WHO scientific consultation. Geneva, Switzerland 1-3 October 2007, World Health Organization, WHO, Geneva.
4. Osterhaus A.D.M.E. Pre- or post-pandemic influenza vaccine. Vaccine 2007, 25:4983-4984.
5. United States Food and Drug Administration (USFDA). First " bird flu" vaccine for humans approved [Internet]. Available: [accessed 08.10.10]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108892.htm.
6. Chu D.W.-S., Hwang S.J., Lim F.S., Oh H.M.L., Thongcharoen P., Yang P.C., et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435.
7. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
8. Leroux-Roels I., Bernhard R., Gerard P., Dramé M., Hanon E., Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3(2):e1665.
9. Rümke H.C., Bayas J.M., Ramón de Juanes J., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-2388.
10. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products. Available from: [accessed 9.11.10]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003872.pdf.
11. FDA Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007 [Internet]. Available: [accessed 15.09.10]. http://www.fda.gov/cber/gdlns/panfluvac.htm.
12. Global Alert and Response. Current WHO phase of pandemic alert for avian influenza H5N1 [Internet]. Available: [accessed 12.01.11]. http://www.who.int/csr/disease/avian_influenza/phase/en/index.html.
13. Seasonal Flu: International Situation Update. Global Flu Activity Update [Internet]. Available from: [accessed 12.01.11]. http://www.cdc.gov/flu/international/activity.htm.
14. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines [Internet]. Available from: [accessed 04.02.11]. http://www.who.int/csr/disease/avian_influenza/guidelines/201009_H5_H9_VaccineVirusUpdate.pdf.
15. Schwarz T.F., Horacek T., Knuf M., Damman H.G., Roman F., Dramé M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-6290.
16. Leroux-Roels I., Roman F., Forgus S., Maes C., De Boever F., Dramé M., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
17. World Health Organization. Global Alert and Response. Availability of a new recombinant H5N1 vaccine virus, May 2009 [Internet]. Available from: [accessed 18.10.10]. http://www.who.int/csr/disease/avian_influenza/H5N1virus26May/en/index.html.
18. Lerous-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9:1057-1071.
19. Díez-Domingo J., Garcés-Sanchez M., Baldó J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010, 29:e35-e46.